Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Study of Imaging Genomics Based on Machine Learning for BCIG

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04461990
Recruitment Status : Not yet recruiting
First Posted : July 8, 2020
Last Update Posted : July 8, 2020
Sponsor:
Collaborators:
RenJi Hospital
International Peace Maternity and Child Health Hospital
Information provided by (Responsible Party):
Guyajia, Fudan University

Brief Summary:
  1. Identify the imaging features of breast cancer with different molecular types
  2. Reveal the association between hormone receptor positive/HER2 negative breast cancer and imaging histology, Oncotype Dx recurrence score
  3. Combine genomics and imaging to establish a predictive model for the sensitivity of HER2-positive breast cancer targeted therapy
  4. Establish an imaging genomics prediction model for triple-negative breast cancer molecular subtypes, and clarify the imaging genomics characteristics of the therapeutic targets of each subtype

Condition or disease Intervention/treatment
Breast Cancer Molecular Typing Pathology Image, Body Procedure: Multidisciplinary cooperative comprehensive treatment

Detailed Description:

Research design

  1. Research on the molecular typing of breast cancer based on imaging features
  2. Establish a Luminal breast cancer recurrence risk prediction model
  3. Establish HER2 targeted therapy sensitivity prediction model
  4. Establish TNBC molecular subtype prediction model Research methods Research Object This study used a multi-center study to prospectively enroll breast cancer patients diagnosed with pathology. All enrolled patients had complete clinical data, including demographic characteristics (gender, age, menstrual status and fertility history), and pathological data (histopathological data). Staging, immunohistochemical status and FISH, genetic testing records the recurrence score and genotype), imaging data, complete treatment and follow-up (whether there is local recurrence and metastasis, and the time of diagnosis).

Magnetic resonance examination In order to maintain the comparability between the images and reduce the systematic errors, each center selects a fixed MR device for scanning. Among them, a. Oncology Hospital chose to scan images with 3.0T (Siemens Skyra) MR equipment. A special breast coil is used to add high-definition diffusion-weighted scanning and multi-b value diffusion-weighted scanning before the dynamic enhancement scan. Dynamically enhanced acquisition in 5 phases with a time resolution of 65s. b. Renji Hospital uses Netherlands Philips Achieva 3.0 T superconductor MR scanner, 4-channel dedicated breast phased array coil. Scanning sequences include T1WI, T2WI, T2WI fat suppression, DWI and DCE-MRI. The contrast agent was Gd-DTPA, with a dose of 0.1 mmol/kg, an injection rate of 2.0 mL/s, and an additional 20 mL of saline was added to the tube after injection. The T1WI scan was performed first, and 5 time phases were continuously scanned after the injection of contrast agent, and each time phase was separated by 61 s, for a total of 6 time phases. c. Chinese women and babies are scanned with 1.5T SIEMENS AERA MR equipment and special breast coils. Scanning sequence includes 5 phases of T1WI, T2WI fat suppression, DWI and dynamic enhancement scan, time resolution 71s.

Image processing Use software to make semi-automatic and automatic outlines of the tumor interest area, and make the outline of the tumor solid enhancement part, the entire tumor area and the surrounding edema zone in the transverse position. In order to accurately delineate the tumor, compare the T1 and T2 weighted and dynamically enhanced images, two imaging physicians are responsible, one is responsible for delineation and the other is reviewed, and the disputed area is determined after discussion by a third person. Create a dynamic enhanced tumor texture analysis program to automatically extract imaging omics features in the region of interest. Using a labeled data set, a computer-based automatic segmentation algorithm model based on machine learning is constructed to automatically extract regions of interest, and segmentation performance evaluation is performed on manually delineated labels.

Statistical analysis Perform statistical analysis on the obtained images and clinical data, extract image omics features and use machine learning algorithms to screen important features. Use statistical tools such as SPSS and R language. Paired t test (continuous variable) and chi-square test (discontinuous variable) were used to compare the clinical and imaging characteristics of patients with different prognosis; correlation analysis was used to evaluate the imaging histology characteristics and different pathological tissue grades, Correlation between lymph node metastasis and specific gene expression; use Kaplan-Meier survival curve to analyze the prognostic difference between patients with different imaging omics characteristics, and use log-rank method to test the difference; use cox survival model to compare clinical characteristics and imaging omics The characteristics and prognosis of patients (tumor-free survival, progression-free survival, overall survival) were analyzed by multiple factors. Further, deep learning algorithms can be used to automatically learn imaging omics features that may be related to molecular subtypes and prognosis to build prediction models.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 1500 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 5 Years
Official Title: Clinical Study of Imaging Genomics Based on Machine Learning for Breast Cancer Molecular Typing and Risk Prediction (BCIG)
Estimated Study Start Date : December 1, 2020
Estimated Primary Completion Date : December 30, 2022
Estimated Study Completion Date : December 30, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Group/Cohort Intervention/treatment
Luminal

Luminal A:ER+ and/or PR+,HER2- Luminal B:ER+ and/or PR+,HER2+

* ER:estrogen receptor PR:progesterone receptor HER2:human epidermalgrowth factor receptor-2

Procedure: Multidisciplinary cooperative comprehensive treatment
Local surgery, radiation therapy, and systemic therapy such as chemotherapy, endocrine and molecular targeting.

HER2 overexpression

ER- PR-,HER2+

* ER:estrogen receptor PR:progesterone receptor HER2:human epidermalgrowth factor receptor-2

Procedure: Multidisciplinary cooperative comprehensive treatment
Local surgery, radiation therapy, and systemic therapy such as chemotherapy, endocrine and molecular targeting.

Triple negative

ER- PR-,HER2-

* ER:estrogen receptor PR:progesterone receptor HER2:human epidermalgrowth factor receptor-2

Procedure: Multidisciplinary cooperative comprehensive treatment
Local surgery, radiation therapy, and systemic therapy such as chemotherapy, endocrine and molecular targeting.




Primary Outcome Measures :
  1. Image prediction model of different molecular typing [ Time Frame: 30 December,2022----30 December,2023 ]
    1. Build a model to predict molecular typing based on image
    2. Establish a prediction model for predicting the risk of Luminal breast cancer recurrence
    3. Establish a prediction model for predicting her2 targeted drug resistance
    4. Establishing a triple-negative molecular model for breast cancer



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Prospectively enrolled breast cancer patients diagnosed by pathology, all clinical data of all enrolled patients are complete, including demographic characteristics (gender, age, menstrual status and fertility history), pathological data (staging in histopathology, immunohistochemistry) Status and FISH, genetic testing records the recurrence score and genotype), imaging data, complete treatment and follow-up (whether there is local recurrence and metastasis, and the time of diagnosis)
Criteria

Inclusion Criteria:

  1. Pathological and immunohistochemical diagnosis of breast cancer by biopsy
  2. No MRI contraindications and no biopsy before MRI
  3. Without radiotherapy and chemotherapy before enrollment

Exclusion Criteria:

  1. Those with previous history of breast cancer surgery, hormone replacement therapy and chest radiotherapy
  2. Patients with severe diseases who cannot cooperate with the examination
  3. People with contraindications to MRI
  4. The researchers believe that other conditions are not suitable for breast MRI examination

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04461990


Contacts
Layout table for location contacts
Contact: Gu Ya Jia 86-18017317817 guyajia@126.com

Locations
Layout table for location information
China, Shanghai
Fudan University Shanghai Cancer Center
Shanghai, Shanghai, China, 200032
Contact: Gu Ya Jia    86-18017312040    guyajia@126.com   
Principal Investigator: Hua jia         
Principal Investigator: Qian zhaoxia         
Principal Investigator: Wang he         
Sub-Investigator: You chao         
Sub-Investigator: Zhuang zhiguo         
Sub-Investigator: Jiang ling         
Sub-Investigator: Zheng rencheng         
Sub-Investigator: Xiao qin         
Sub-Investigator: Chen yanqiong         
Sub-Investigator: Hu xiaoxin         
Sponsors and Collaborators
Fudan University
RenJi Hospital
International Peace Maternity and Child Health Hospital
Investigators
Layout table for investigator information
Principal Investigator: Gu Ya Jia Fudan University
Layout table for additonal information
Responsible Party: Guyajia, Director of Radiology, Fudan University
ClinicalTrials.gov Identifier: NCT04461990    
Other Study ID Numbers: BCIG
First Posted: July 8, 2020    Key Record Dates
Last Update Posted: July 8, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Guyajia, Fudan University:
breast cancer
Pathology
Molecular Typing
magnetic resonance
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases